Inventor

Glenn Dranoff

Inventor

Lexington, MA, US

Overview

26→

Patents

1997–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 26 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes30%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%

C07KPeptides20%

C12NMicroorganisms or enzymes11%

A61NElectrotherapy4%

A61QSpecific use of cosmetics or similar toiletry preparations2%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

PatentTitleYear

10,876,120Methods and compositions for reducing immunosupression by tumor cells2020 10,865,233NKG2D-fc for immunotherapy2020 10,865,232NKG2D-IG fusion protein for cancer immunotherapy2020 10,851,165Antibody molecules to PD-L1 and methods of treating cancer2020 10,793,633Therapeutic peptides2020 10,786,491Immunomodulation by IAP inhibitors2020 10,745,483Therapeutic peptides2020 10,682,400Combination vaccine devices and methods of killing cancer cells2020 10,662,247Compositions and methods of use for augmented immune response and cancer therapy2020 10,568,949Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices2020 10,328,133Continuous cell programming devices2019 10,279,021Vaccine compositions and methods for restoring NKG2D pathway function against cancers2019 10,258,677Continuous cell programming devices2019 10,226,476Method of attenuating reactions to skin irritants2019 10,106,611Antibodies that bind to MHC class I polypeptide-related sequence A2018 9,988,452Antibody molecules to PD-L1 and uses thereof2018 9,944,931Methods and compositions for reducing immunosupression by tumor cells2018 9,821,045'Controlled delivery of TLR3 agonists in structural polymeric devices'2017 9,750,729'Immunomodulation by IAP inhibitors'2017 9,492,518'Tumor immunity'2016 9,402,905'Therapeutic peptides'2016 9,370,558'Controlled delivery of TLR agonists in structural polymeric devices'2016 7,419,958'Method of attenuating reactions to skin irritants'2008 7,250,291'Tumor antigens and uses thereof'2007 5,904,920'Regulation of systemic immune responses utilizing cytokines and antigens'1999 5,637,483'Irradiated tumor cell vaccine engineered to express GM-CSF'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2020Based in Lexington, MA, US· patent location history

2007–2020Patents assigned to DANA FARBER CANCER INST INC (22)· patent assignee history

2016–2020Patents assigned to HARVARD COLLEGE (8)· patent assignee history

2016–2020Patents assigned to DRANOFF GLENN (4)· patent assignee history

2016–2020Based in Sudbury, MA, US· patent location history

2017–2020Patents assigned to NOVARTIS AG (5)· patent assignee history

2018–2020Patents assigned to MASSACHUSETTS GEN HOSPITAL (2)· patent assignee history

2018Based in Cambridge, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
DANA FARBER CANCER INST INC	22	2007–2020
HARVARD COLLEGE	8	2016–2020
NOVARTIS AG	5	2017–2020
DRANOFF GLENNself	4	2016–2020
MASSACHUSETTS GEN HOSPITAL	2	2018–2020

Locations

Location	Patents	Span
Lexington, Massachusetts, US	13	1997–2020
Sudbury, Massachusetts, US	12	2016–2020
Cambridge, Massachusetts, US	1	2018